刘革新代言的产品为科伦药业旗下川宁生物的一款叫做"麦角硫因"的生物提取物，产品宣称具有抗衰功能。不过，有业内人士表示："这种物质的实际功效 以及应用的边界仍然需要进一步验证。" 近日，科伦药业董事长刘革新出现在一个保健品广告视频中。广告中，刘革新以"75岁刘先生"的"赤膊"形象出现，并称："没有什么不可能。" 七旬董事长"赤膊上阵"亲自带货，也折射出传统药企在新形势下面临的挑战。 据悉，刘革新代言的产品为科伦药业旗下川宁生物的一款叫做"麦角硫因"的生物提取物，产品宣称具有抗衰功能。不过，有业内人士表示："这种物质的实 际功效以及应用的边界仍然需要进一步验证。" 上个月，科伦药业财报显示，2025年一季度，公司实现营业收入43.9亿元，同比下降近30%；净利润5.84亿元，同比下滑超过43%；2022年至2024年，科伦 药业销售费已连续三年下滑，输液业务受集采影响是收入下降的重要原因。此外，川宁生物的原料药/中间体价格有所波动。 根据福布斯富豪榜最新数据，作为科伦药业的掌舵者，刘革新个人财富目前已经达到17亿美元（约合122.6万元人民币），较科伦药业上市首日55亿元人民 币的个人财富翻了一倍多。另据科伦药业 ...

Core Insights - The article emphasizes the importance of extending healthy life expectancy in the context of an aging population, highlighting the role of gut microbiota in aging and chronic inflammation [1][4]. Company Overview - Guangxi Aisheng Life Technology Co., Ltd. (Aisheng Life) is a national high-tech enterprise focused on longevity research, having established the world's largest longevity human database and microbiome library [1][4]. - The company has published multiple longevity research findings in renowned international journals over its 7+ years of operation, showcasing its influence in the field [1][4]. Recent Research Achievements - Aisheng Life's research team published a paper in the journal Aging Cell, exploring the causal relationships between gut microbes, aging indicators, and age-related diseases, revealing the potential of gut microbiota as biomarkers for health management and disease prevention [4][5]. - The study innovatively integrated gut microbiota, various aging indicators, and numerous age-related diseases into a comprehensive research framework, confirming the significant role of gut microbiota in aging and disease [5][7]. Research Methodology and Findings - The research utilized Mendelian randomization (MR) and linkage disequilibrium score regression (LDSC) to analyze the genetic correlations and causal relationships between gut microbiota and three aging indicators (telomere length, frailty index, and facial aging) as well as 14 age-related diseases (e.g., coronary heart disease, chronic kidney disease, Alzheimer's disease) [5][7]. - Specific gut microbes, such as Bifidobacterium breve, were found to be associated with delayed aging and reduced disease risk, while the enrichment of pathogenic bacteria could increase chronic inflammation and metabolic disorders [5][7]. Predictive Models and Applications - The research team developed predictive models for nine age-related diseases based on identified gut microbes, achieving an average AUC value of 0.832, indicating strong predictive performance [7][10]. - The findings suggest that gut microbiota can causally influence aging indicators by regulating short-chain fatty acid (SCFA) production, improving gut barrier function, and reducing chronic inflammation [7][8]. Future Directions - The study lays a theoretical foundation for developing targeted interventions against aging by modulating gut microbiota, providing new directions for health management, disease early screening, and personalized interventions [8][9]. - Aisheng Life aims to align its development philosophy with national strategies, promoting the application of longevity research outcomes and expanding the global longevity market [8][9]. Innovations and Patents - Aisheng Life has received national invention patent authorization for a probiotic strain (Lactobacillus A21013 and A21033) that has demonstrated efficacy in extending lifespan, reducing fat, enhancing exercise capacity, and improving stress resistance [12]. - The company has also patented another strain (Lactobacillus A21041) with anti-inflammatory and antioxidant properties, which has shown potential in extending lifespan and reducing fat, indicating high practical value for developing longevity products [13][16].

Core Viewpoint - Kelong Pharmaceutical's chairman, Liu Gexin, promotes the company's anti-aging product, "Methylthioadenosine Capsules," in a striking advertisement, showcasing his fitness at the age of 75, which has generated significant social media buzz [1][2]. Company Overview - Kelong Pharmaceutical (002422.SZ) has a market capitalization of 54.558 billion yuan and a stock price of 34.14 yuan [1]. - The company is exploring the health and wellness sector as a potential growth avenue, especially after experiencing a decline in revenue and net profit in the first quarter of the year [6]. Product Details - The "Methylthioadenosine Capsules" are marketed at 1,499 yuan per bottle (60 capsules), with each capsule containing 30 mg of the active ingredient [3]. - The product claims to have antioxidant effects that are 10 to 30 times more effective than traditional ingredients like Vitamin C and Coenzyme Q10 [3]. - The capsules are sold through online platforms and Japanese physical stores, with plans for further online sales on JD Overseas and Tmall International [6]. Marketing Strategy - Liu Gexin has been using the product for three years and maintains a strict fitness regimen, which the company emphasizes in its marketing [2][6]. - The advertisement has sparked discussions on social media, indicating a successful initial marketing impact [2]. Industry Context - The high-end anti-aging health product market is competitive, and consumer acceptance of the product's efficacy will take time to establish [6]. - Methylthioadenosine is gaining attention in the skincare and health supplement sectors for its potential anti-aging properties, although large-scale human trial data is still limited [6][7].

Core Viewpoint - Kelong Pharmaceutical is entering the health and wellness sector with a focus on ergothioneine, a compound believed to have significant anti-aging properties, as indicated by the company's chairman, Liu Gexin [1][5]. Company Overview - Kelong Pharmaceutical was founded in 1996 by Liu Gexin, who has served as chairman since its inception [1]. - The company has faced challenges in its traditional pharmaceutical business, including a decline in demand for infusion products and increased competition in the generic drug market [4]. - Kelong Pharmaceutical's revenue for Q1 2025 was 4.39 billion yuan, a decrease of 29.42% year-on-year, with net profit dropping by 43.07% to 584 million yuan [4]. Product Development - The upcoming ergothioneine product is set to launch in mid-May, coinciding with Kelong's 29th anniversary [1]. - The raw materials for ergothioneine are supplied by Kelong's subsidiary, Chuaning Bio, which specializes in biotechnological products [2]. - Ergothioneine is reported to have seven health benefits, including anti-aging, sleep improvement, cognitive enhancement, skin health, anti-inflammation, diabetes prevention, and cardiovascular protection [2]. Marketing Strategy - Kelong has established a sales platform named Kelong Yongnian, which is primarily responsible for marketing health products [4]. - The company aims to leverage the personal endorsement of its 75-year-old chairman to enhance the product's market appeal [5]. - Kelong is preparing to launch over ten anti-aging products, indicating a strategic shift towards health and wellness [5]. Industry Context - The health and wellness market is seen as a promising growth area, particularly in anti-aging products, which are gaining traction among consumers [1][5]. - Kelong's entry into this sector reflects a broader trend in the pharmaceutical industry, where companies are diversifying their offerings to adapt to changing market demands [4].

Core Insights - Japan's medical beauty market has surpassed 600 billion yen (approximately 30.2 billion RMB), exceeding that of South Korea, which is known as a "cosmetic surgery powerhouse" [1][3] - The market is expected to continue growing, driven by advancements in medical technology and changing social attitudes towards cosmetic procedures [3][4] Market Size and Growth - The Japanese medical beauty market was valued at 486 billion yen in 2021, representing a 120% increase from the previous year [3] - In 2023, the market is projected to reach 594 billion yen, marking a growth of 108.8% compared to 2022 [3] - From 2009 to 2023, the market has expanded 2.39 times, indicating robust growth [3] Consumer Behavior and Trends - Approximately 70% of surveyed individuals aged 15 to 49 express concern about their appearance, with 43% considering some form of cosmetic medical treatment [4] - The rise of social media has contributed to a more open attitude towards cosmetic procedures, with many celebrities and influencers openly discussing their experiences [3][4] - Non-surgical treatments, such as laser therapy and hyaluronic acid injections, are particularly popular among consumers [4] Demographic Insights - Male consumers are increasingly participating in cosmetic procedures, with treatments like beard removal gaining popularity for their time-saving benefits [4]

Core Viewpoint - The recent study challenges the belief that NAD+ depletion significantly impacts muscle function and accelerates aging, suggesting that muscle health may not be as dependent on NAD levels as previously thought [2][5][11]. Group 1: Study Findings - The study utilized an inducible skeletal muscle-specific Nampt gene knockout (iSMNKO) mouse model, resulting in an 85% reduction in NAD+ levels without affecting muscle mass, integrity, contraction strength, or exercise performance [2][9]. - Even with lifelong NAD+ depletion, the mice did not exhibit accelerated muscle aging or systemic metabolic impairment [8][9]. - The research indicates that skeletal muscle can tolerate significant NAD+ depletion without losing functionality or accelerating aging, contradicting the common belief that NAD+ reduction is a primary driver of muscle aging and weakness [5][11]. Group 2: Implications for NAD+ Supplementation - The findings raise questions about the efficacy of NAD+ supplementation as an anti-aging strategy, suggesting that it may be a waste of resources [5][11]. - The study's leader emphasized that the results challenge the notion that reduced NAD+ levels are a major factor in muscle aging and weakness [5][11]. - The research highlights the need for further investigation into the extent to which NAD+ reduction affects mitochondrial function and the aging process [6][11].